GCG and Hyperglycemia: Compared to placebo, GLP-2 infusion significantly reduced bsAUC for PINP during euglycemia (141 ± 304 [placebo] vs −325 ± 256 ng/mL × min [GLP-2]; P = .003) and hyperglycemia (−154 ± 387 [placebo] vs −718 ± 387 ng/mL × min [GLP-2]; P = .0009) (Fig. 3E and 3F, Table 3).